Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRMT7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRMT7 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW optimized for assay compatibility. |
View PRMT7 Products |
| Gene Delivery | PRMT7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View PRMT7 Products |
| Benchmark Ab | Anti-PRMT7 Benchmark Antibody Recombinant positive control for target verification and Western Blot/IP. |
View PRMT7 Products |
| Validator | PRMT7 siRNA Set For knockdown verification and specificity profiling. |
View PRMT7 Products |
| Related Target A | PRMT5 Major Type II PRMT often screened alongside PRMT7 to ensure selectivity and avoid off-target toxicity. |
View PRMT5 Products |
| Related Target B | PRMT1 Primary Type I PRMT involved in asymmetric dimethylation, crucial for profiling methyltransferase selectivity panels. |
View PRMT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Selectivity Profiling | High-purity, sequence-verified PRMT7, PRMT5, and PRMT1 proteins available for robust cross-family counter-screening. |
| In vitro Activity Assay Interference | Endotoxin-controlled, high-purity protein formulations ensuring minimal assay background and high signal-to-noise ratios. |
| Lack of Controls | Sequence-validated recombinant benchmark antibodies included for target engagement and expression verification. |
| False Positives in Small Molecule Screens | Validated siRNA knockdown sets included for orthogonal biological validation in target-dependent cell lines. |
Live PRMT7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRMT7 therapeutics is intensifying, with major players shifting focus from broad-spectrum methyltransferase inhibitors to highly selective small molecules and PROTACs. As first-generation PRMT inhibitors (such as those targeting PRMT5) navigate clinical safety hurdles, the next wave of R&andD is targeting PRMT7 due to its unique role in monomethylation (MMA), immune cell regulation, and tumor metastasis. Developing selective PRMT7 inhibitors requires precise screening platforms to avoid cross-reactivity with other PRMT family members.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Epizyme (Ipsen), GSK, Academic Consortia | Breast Cancer, Colorectal Cancer, Immunotherapy Resistance | Selectivity Assay (Need highly purified WT PRMT7 vs PRMT1/5 panels) |
| PROTAC / Degraders | Biotech Startups, Research Institutes | Metastatic Solid Tumors, Hematological Malignancies | Target Engagement & Degradation Assay (Need Lentivirus for stable cell lines) |